insulin

In a report issued Tuesday morning, Jefferies analyst Shaunak Deepak adjusted his estimates for MannKind Corporation (NASDAQ: MNKD)'s Afrezza based on physician feedback, in spite of early IMS scripts. According to the analyst, the feedback has made the firm more confident in the long-term...